Medical Microbiology and Immunology

, Volume 207, Issue 5–6, pp 249–253 | Cite as

Preventing vertical virus infections: the role of serologic screening of pregnant women

  • Annemarie BergerEmail author
  • Hans Wilhelm Doerr


Several virus infections affect the pregnancy itself as well as the foetal development (rubella, PVB19, VZV, HSV, HCMV, HBV, HIV). Prevention can be established by vaccination or an assessment of the immunity status as well as by chemotherapy. The following review provides an update to current aspects focusing on the role of serologic screening.


Pregnancy Vertical virus infections Serologic screening 



We greatly thank Andrea Doerr for editing the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    WHO Fact Sheet Rubella, updated November 2017. Accessed 3 Jul 2018
  2. 2.
    Vauloup-Fellous C (2018) Standardization of rubella immunoassays. J Clin Virol 102:34–38CrossRefGoogle Scholar
  3. 3.
    Robert-Koch-Institut (2010) Änderung der Empfehlungen zur Impfung gegen Röteln. Epidemiol Bull 32:322–325. Accessed 3 Jul 2018
  4. 4.
    Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Leitlinie: Labordiagnostik schwangerschaftsrelevanter Virusinfektionen. S2k-Leitlinie AWMF Registernummer 0093/001 Stand: 31.03.2014. Accessed 12 Feb 2018
  5. 5.
    Bonvicini F. Bua G, Gallinella G (2017) Parvovirus B19 infection in pregnancy-awareness and opportunities. Curr Opin Virol 27:8–14CrossRefGoogle Scholar
  6. 6.
    Public Health Laboratory Service Working Party on Fifth Disease (1990) Prospective study of human parvovirus (B19) infection in pregnancy. BMJ 300:1166–1170CrossRefGoogle Scholar
  7. 7.
    Rodis JF, Quinn DL, Gary GW Jr, Anderson LJ (1990) Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 163:1168–1171CrossRefGoogle Scholar
  8. 8.
    Reinheimer C, Allwinn R, Doerr HW, Wittek M (2010) Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors. Infection 38:381–385CrossRefGoogle Scholar
  9. 9.
    Barlinn R, Rollag H, Trogstad L et al (2017) High incidence of maternal parvovirus B19 infection in a large unselected population-based pregnancy cohort in Norway. J Clin Virol 94:57–62CrossRefGoogle Scholar
  10. 10.
    Bredl S, Plentz A, Wenzel JJ, Pfister H, Möst J, Modrow S (2011) False-negative serology in patients with acute parvovirus B19 infection. J Clin Virol 51:115–120CrossRefGoogle Scholar
  11. 11.
    Crane J, Mundle W, Boucoiran I et al (2014) Parvovirus B19 in pregnancy. J Obstet Gynaecol Can 36:1107–1116CrossRefGoogle Scholar
  12. 12.
    Matsuda H, Sakaguchi K, Shibasaki T, Takahashi H, Kawakami Y, Furuya K (2005) Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med 33:561–563Google Scholar
  13. 13.
    Pasternak B, Hviid A (2010) Use of acyclovir, valacyclovir and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304:859–866CrossRefGoogle Scholar
  14. 14.
    Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: varicella-zoster virus infections. Med Microbiol Immunol 196:95–102CrossRefGoogle Scholar
  15. 15.
    Wiese-Posselt M, Siedler A, Mankertz A et al (2017) Varicella-zoster virus seroprevalence in children and adolescents in the pre-varicella vaccine era, Germany. BMC Infect Dis 17:356CrossRefGoogle Scholar
  16. 16.
    Werner RN, Nikkels AF, Marinović B et al (2017) European consensus-based (S2k) guideline on the management of herpes zoster—guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), part 1: diagnosis. J Eur Acad Dermatol Venereol 31:9–19CrossRefGoogle Scholar
  17. 17.
    Doerr HW (2013) Progress in VZV vaccination? Some concerns. Med Microbiol Immunol 202:257–258CrossRefGoogle Scholar
  18. 18.
    Wicker S, Rabenau HF, Gottschalk R, Doerr HW, Allwinn R (2007) Seroprevalence of vaccine preventable and blood transmissible viral infections (measles, mumps, rubella, VZV, polio, HBV, HCV and HIV) in medical students. Med Microbiol Immunol 196:145–150CrossRefGoogle Scholar
  19. 19.
    Wittek M, Doerr HW, Allwinn R (2010) Varicella and herpes zoster. Part 1: virology, epidemiology, clinical picture, laboratory diagnostics. Med Klin (Munich) 105:334–338CrossRefGoogle Scholar
  20. 20.
    Buxbaum S, Geers M, Gross G, Schöfer H, Rabenau HF, Doerr HW (2003) Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed? Med Microbiol Immunol 192:177–181CrossRefGoogle Scholar
  21. 21.
    Gupta R, Warren T, Wald A (2007) Genital herpes. Lancet 370:2127–2137CrossRefGoogle Scholar
  22. 22.
    Kimberlin D (2004) Neonatal herpes simplex infection. Clin Microbiol Rev 17(1):1–13CrossRefGoogle Scholar
  23. 23.
    Hollier LM, Wendel GD (2008) Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Rev 1:CD004946Google Scholar
  24. 24.
    Pichler M, Staffler A, Bonometti N, Messner H, Deluca J, Thuile T, Kluge R, Schmuth M, Eisendle K (2015) Premature newborns with fatal intrauterine herpes simplex virus-1 infection: first report of twins and review of the literature. J Eur Acad Dermatol Venereol 29:1216–1220CrossRefGoogle Scholar
  25. 25.
    Doerr HW, Berger A (2014) Vaccination against infectious diseases. What is promising? Med Microbiol Immunol 203:365–371CrossRefGoogle Scholar
  26. 26.
    Lübeck PR, Doerr HW, Rabenau HF (2010) Epidemiology of human cytomegalovirus (HCMV) in an urban region of Germany: what has changed? Med Microbiol Immunol 199:53–60CrossRefGoogle Scholar
  27. 27.
    Enders G, Daiminger A, Lindemann L, Knotek F, Bäder U, Exler S, Enders M (2012) Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996–2010. Med Microbiol Immunol 201:303–309CrossRefGoogle Scholar
  28. 28.
    Rycel M, Wujcicka W, Zawilińska B, Paradowska E, Suski P, Gaj Z, Wilczyński J, Leśnikowski Z, Nowakowska D (2015) Mixed infections with distinct cytomegalovirus glycoprotein B genotypes in Polish pregnant women, foetuses, and newborns. Eur J Clin Microbiol Infect Dis 34:585–591CrossRefGoogle Scholar
  29. 29.
    Kagan KO, Hamprecht K (2017) Cytomegalovirus in pregnancy. Arch Gynecol Obstet 296:15–26CrossRefGoogle Scholar
  30. 30.
    Doerr HW (1987) Cytomegalovirus infection in pregnancy. J Virol Methods 17:127–132CrossRefGoogle Scholar
  31. 31.
    Britt W (2015) Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy. Med Microbiol Immunol 204:263–271CrossRefGoogle Scholar
  32. 32.
    Berger A, Reitter A, Harter PN, Buxmann H, Allwinn R, Louwen F, Doerr HW (2011) Problems and challenges in the diagnosis of vertical infection with human cytomegalovirus (CMV): lessons from two accidental cases. J Clin Virol 51:285–288CrossRefGoogle Scholar
  33. 33.
    Doerr HW (2016) Fighting cytomegalovirus-caused diseases: the immunologic approach. Med Microbiol Immunol 205:511–512CrossRefGoogle Scholar
  34. 34.
    Lanzieri TM, Dollard SC, Josephson CD, Schmid DS, Bialek SR (2013) Breast milk-acquired cytomegalovirus infection and disease in very low birth weight and premature infants. Pediatrics 131(6):e1937–e1945CrossRefGoogle Scholar
  35. 35.
    Reitter A, Buxmann H, Haberl AE, Schlösser R, Kreibich M, Keppler OT, Berger A (2016) Incidence of CMV co-infection in HIV-positive women and their neonates in a tertiary referral centre: a cohort study. Med Microbiol Immunol 205:63–71CrossRefGoogle Scholar
  36. 36.
    Wagner N, Kagan KO, Haen S, Schmidt S et al (2014) Effective management and intrauterine treatment of congenital cytomegalovirus infection: review article and case series. J Matern Fetal Neonatal Med 27:209–214CrossRefGoogle Scholar
  37. 37.
    Seidel V, Feiterna-Sperling C, Siedentopf JP, Hofmann J et al (2017) Intrauterine therapy of cytomegalovirus infection with valganciclovir: review of the literature. Med Microbiol Immunol 206:347–354CrossRefGoogle Scholar
  38. 38.
    Rawlinson W (2017) Congenital CMV international guidelines are needed to guide diagnosis, prevention and management. Acta Paediatr 106(9):1389–1390CrossRefGoogle Scholar
  39. 39.
    Hamprecht K, Kagan KO, Schampera M, Jahn G (2018) Impact of pharmacokinetics on the efficiency of CMV-specific hyperimmune globulin treatment in early CMV-primary infection during pregnancy (abstract). In: 28th annual meeting of the Society for Virology, March 14–17, Würzburg, OP 137Google Scholar
  40. 40.
    Plotkin S (2015) The history of vaccination against cytomegalovirus. Med Microbiol Immunol 204:247–254CrossRefGoogle Scholar
  41. 41.
    Mocarski ES (2015) Stanley Plotkin: the bright spark of cytomegalovirus vaccines. Med Microbiol Immunol 204:243–245CrossRefGoogle Scholar
  42. 42.
    Plachter B (2016) Prospects a vaccine for the prevention of congenital cytomegalovirus disease. Med Microbiol Immunol 205:537–547CrossRefGoogle Scholar
  43. 43.
    Mavilia MG, Wu GY (2017) Mechanisms and prevention of vertical transmission in chronic viral hepatitis. J Clin Transl Hepatol 5:119–129 (Review) CrossRefGoogle Scholar
  44. 44.
    Nakagawa F, Phillips AN, Lundgren JD (2014) Update on HIV in Western Europe. Curr HIV/AIDS Rep 11:177–185 (Review) CrossRefGoogle Scholar
  45. 45.
    Vrazo AC, Firth J, Amzel A, Sedillo R, Ryan J, Phelps BR (2018) Interventions to significantly improve service uptake and retention of HIV-positive pregnant women and HIV-exposed infants along the PMTCT continuum of care. A systematic review. Trop Med Int Health 23:136–148CrossRefGoogle Scholar
  46. 46.
    Park JS, Pan CQ (2017) Viral factors for HBV mother-to-child transmission. Hepatol Int 11:476–480CrossRefGoogle Scholar
  47. 47.
    Weis N, Cowan S, Hallager S, Dröse S et al (2017) Vertical transmission of hepatitis B virus during pregnancy and delivery in Denmark. Scand J Gastroenterol 52:178–184CrossRefGoogle Scholar
  48. 48.
    Tavakolpour S, Darvishi M, Mirsafaei HS, Ghasemiadl M (2018) Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond) 50:95–106Google Scholar
  49. 49.
    Gerlich WH (2015) Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol 204:39–55CrossRefGoogle Scholar
  50. 50.
    Shouval D. Roggendorf H, Roggendorf M (2015) Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol 204:57–68CrossRefGoogle Scholar
  51. 51.
    Doerr HW (2013) Perspectives of vaccination in adults. Expert Rev Vaccines 12:593–596CrossRefGoogle Scholar
  52. 52.
    Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S2k Leitlinie: Deutsch-Österreichische Leitlinie zur HIV-Therapie in der Schwangerschaft und bei HIVexponierten Neugeborenen. AWMF-Register-Nr.: 055-002 Stand März 2017. Accessed 3 Jul 2018
  53. 53.
    Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S2k Leitlinie: Leitlinien zur antiretroviralen Therapie bei Kindern und Jugendlichen. AWMF-Register-Nr.: 048-011 Klassifikation: S1 Version 03_2013 Stand 17.03.2013. Accessed 3 Jul 2018

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institut für Medizinische VirologieUniversitätsklinikum Frankfurt, Goethe UniversitätFrankfurtGermany

Personalised recommendations